664,000 Shares in Inogen, Inc $INGN Bought by Armistice Capital LLC

Armistice Capital LLC acquired a new position in Inogen, Inc (NASDAQ:INGN) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 664,000 shares of the medical technology company’s stock, valued at approximately $4,668,000. Armistice Capital LLC owned 2.46% of Inogen as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Qube Research & Technologies Ltd increased its stake in shares of Inogen by 38.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 89,213 shares of the medical technology company’s stock valued at $627,000 after purchasing an additional 24,628 shares in the last quarter. Divisadero Street Capital Management LP boosted its position in Inogen by 192.3% during the second quarter. Divisadero Street Capital Management LP now owns 455,389 shares of the medical technology company’s stock worth $3,201,000 after purchasing an additional 299,571 shares in the last quarter. Federated Hermes Inc. grew its holdings in Inogen by 4.6% in the second quarter. Federated Hermes Inc. now owns 423,320 shares of the medical technology company’s stock valued at $2,976,000 after purchasing an additional 18,425 shares during the period. XTX Topco Ltd grew its holdings in Inogen by 20.2% in the second quarter. XTX Topco Ltd now owns 39,928 shares of the medical technology company’s stock valued at $281,000 after purchasing an additional 6,698 shares during the period. Finally, Prudential Financial Inc. increased its position in shares of Inogen by 7.9% in the second quarter. Prudential Financial Inc. now owns 647,188 shares of the medical technology company’s stock valued at $4,550,000 after buying an additional 47,267 shares in the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Inogen in a research report on Monday, December 1st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inogen presently has a consensus rating of “Hold” and an average target price of $11.00.

Inogen Trading Up 1.6%

NASDAQ:INGN opened at $7.02 on Friday. The company has a market cap of $190.58 million, a P/E ratio of -6.95 and a beta of 1.82. Inogen, Inc has a twelve month low of $5.70 and a twelve month high of $12.91. The company’s 50-day moving average price is $7.64 and its 200-day moving average price is $7.39.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Wednesday, November 5th. The medical technology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. The company had revenue of $92.39 million during the quarter, compared to analysts’ expectations of $92.20 million. Inogen had a negative net margin of 7.31% and a negative return on equity of 13.21%. On average, analysts expect that Inogen, Inc will post -1.73 earnings per share for the current year.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.